We also determined the in vivo efficacy of VX-970 in mice with established tumours derived from a tumour cell line with naturally occurring ARID1A mutations (TOV21G, ARID1A p.548fs/p.756fs). The gene discussed is ARID1A; the disease is neoplasm.